|
|||
|
DRUGS & SUPPLEMENTS
|
Cadramine-V
How is the drug helping you? |
Cadramine-V uses
Cadramine-V consists of Calamine, Camphor, Diphenhydramine Hydrochloride, Menthol, Zinc Oxide.Calamine:
Active ingredient
Cadramine-V (Calamine) 8%
Pramoxine HCl 1%
Purpose
Skin protectant
External analgesic
Uses
temporarily relieves pain and itching associated with:
- insect bites
- rashes
- minor skin irritations
- minor cuts
- dries the oozing and weeping of poison ivy, poison oak and poison sumac
Warnings
For external use only. Use only as directed. Intentional misuse by deliberately concentrating and inhailing contents can be harmful or fatal.
Flammable:
Do not use while smoking or near heat or flame. Do not puncture or incinerate. Contents under pressure. Do not store at temperatures above 120°F.
When using this product
- do not get into eyes
- ask a doctor before using on children under 2 years of age
Stop use and ask a doctor if
- conditions worsens
- symtomps last more than 7 days or clear up and occur again in a few days
Keep out of reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- shake well before using
- adults and children 2 years of age and older: apply as needed to the affected area, not more than 3 or 4 times daily
- cleanse the skin with soap and water
- let dry before use
- children under 2 years of age: consult a doctor
Other information
store between 20° to 25°C (68° to 77°F)
Inactive ingredients
benzyl alcohol, camphor, disteardimonium hectorite, fragrance, hydrated silica, isobutane, oleyl alcohol, SD alcohol 40-B, sorbitan trioleate
Questions?
Call 1-866-964-0939
Camphor:
- Drug facts
- Active ingredients
- purpose
- warnings
- directions
- Inactive ingredients
- Other information
- Packaging
Drug Facts
Active ingredients
Cadramine-V (Camphor) 0.70%
Purpose
External analgesic
Uses : For the temporarily relief of pain and itching associated with:
- minor burn, sunburn - minor cuts, scrapes, insect bites
- minor skin problems.
Warnings
For external use only.
Do not use - with other topical pain relievers - with heating pads or heating devices.
When using this product
- do not use in or near eyes - do not apply to wounds or damaged skin - do not bandage tightly
Stop use and ask a doctor if
- condition worsens - symptoms last more than 7 days or clear up and occur again within a few days - redness or irritation develops
If pregnant or breast-feeding ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Centre right away.
Directions
- clean affected area before applying product - adults and children 2 years of age and older: apply to affected area not more than 3 to 4 times daily. - children under 2 years of age: ask a doctor
Inactive ingredients
Aloe vera extract, Arnica Montana extract, Cetyl alcohol, Chamomile extract, Common juniper oil, Common thyme oil, Eucalyptus oil, Glycerin, Horse-chestnut extract, Nipaquard, November EC2, Peppermint oil, Polyglyceryl-3 Stearate/Citrate, Pot marigold oil, Rosemary oil, Scots pine leaf extract, Turmeric extract, Xanthan Gum
Other information
- store at room temperature 59°F-77ºF - keep lid tightly close - do not use, pour, spill or store near heat source or open flame
Questions? Call 239 938 4116
(Monday- Friday, 9 AM- 4PM)
Or write us at: infoCadramine-V (Camphor)hillvitalusa.com
Distributed by:
HILLVITAL USA
P.O. Box 152214
Cape Coral, FL., 33915
Made in Hungary
Hillvital Cadramine-V (Camphor) is made of essential oils and extracts of 12 powerful medicinal herbs. All active substances have the best quality and are 100% natural. Regular use can help to release or dissolve pains. It can help to soothe musculoskeletal aches.
FREE FROM ARTIFICIAL FRAGRANCES
COLOURINGS AND HARMFUL CHEMICALS
NO KNOWN SIDE EFFECTS
NOT TESTED ON ANIMALS
12 natural herbs
MEDICINAL HERBS
Packaging
MasterBalm-2
Diphenhydramine Hydrochloride:
Pharmacological action
Cadramine-V Xepa-Soul Pattinson is a blocker of histamine H1-receptors. It has antiallergic activity, has a local anesthetic, antispasmodic and mild ganglion blocking action.
When Cadramine-V (Diphenhydramine Hydrochloride) Xepa-Soul Pattinson administered orally Cadramine-V (Diphenhydramine Hydrochloride) has a sedative and hypnotic effects, has a moderate antiemetic effect and has a central holinoliticheskoy activity.
When applied externally it has antiallergic effect.
Pharmacokinetics
Cadramine-V (Diphenhydramine Hydrochloride) Xepa-Soul Pattinson is rapidly absorbed from the gastrointestinal tract. Bioavailability is 50%. Cmax is achieved after 20-40 min (in the greatest concentration is determined in the lungs, spleen, kidneys, liver, brain and muscles). Binding to plasma proteins - 98-99%. Penetrates through the BBB. Metabolised mainly in the liver, partly - in the lungs and kidneys. T1/2 is 4-10 hours. Within one day completely removed kidneys as metabolites conjugated to glucuronic acid. Significant quantities are derived from milk and can cause sedation in infants (may be a paradoxical reaction characterized by hyperexcitability).
Why is Cadramine-V Xepa-Soul Pattinson prescribed?
Allergic reactions (urticaria, hay fever, angioedema), allergic conjunctivitis, vasomotor rhinitis, Henoch-Schonlein purpura, serum sickness, itchy dermatitis, sleep disorders (monotherapy or in combination with drugs), chorea, sea and air sickness, vomiting in pregnancy, Meniere's syndrome, premedication.
Dosage and administration
Oral, IV, IM, rectal, topical, intranasal, in the conjunctival sac. Oral dose of Cadramine-V Xepa-Soul Pattinson for adults is 30-50 mg 1-3 times / day. The treatment course is 10-15 days. As soporific - 50 mg at bedtime. IM in doses of 50-250 mg; IV in drip - 20-50 mg. When oral administered single dose for children under 1 year - 2-5 mg; from 2 to 5 years - 5-15 mg; of 6 to 12 years - 15-30 mg. Externally applied 1-2 times / day.
Cadramine-V (Diphenhydramine Hydrochloride) Xepa-Soul Pattinson side effects, adverse reactions
Possible: a short-term numbness in the oral mucosa, drowsiness, weakness, decrease in psychomotor speed of reaction in children may be a paradoxical development of insomnia, irritability, and euphoria.
Rarely: dizziness, headache, dry mouth, nausea, photosensitivity, paresis of accommodation, poor coordination of movements, tremor.
Cadramine-V Xepa-Soul Pattinson contraindications
Closure glaucoma, prostatic hypertrophy, stenosing peptic ulcer, stenosis of the bladder neck, bronchial asthma, epilepsy, hypersensitivity to Cadramine-V (Diphenhydramine Hydrochloride).
Using during pregnancy and breastfeeding
During pregnancy and lactation, Cadramine-V (Diphenhydramine Hydrochloride) used with caution, according to strict indications, when the expected therapeutic effect for the mother outweighs the potential risk to the fetus or infant.
Special instructions
With careful use Cadramine-V (Diphenhydramine Hydrochloride) during pregnancy and lactation.
During the period of treatment with Cadramine-V (Diphenhydramine Hydrochloride) Xepa-Soul Pattinson should not be exposed to solar radiation should be avoided alcohol.
Used with caution in patients involved in potentially dangerous activities requiring attention and rapid psychomotor reactions.
Precautionary measures
Cadramine-V Xepa-Soul Pattinson is not recommended for SC injection. Since Cadramine-V (Diphenhydramine Hydrochloride) has atropinopodobnym action should be cautious in its use: patients with recent respiratory infection in history (including asthma), increased intraocular pressure in hyperthyroidism, cardiovascular system, hypotension. Antihistamines drugs can reduce mental alertness as well as in adults and children and also cause agitation and hallucinations, convulsions and death in infants and children, especially in overdose. Precautions apply at age 60 and older because more likely to develop dizziness, sedation and hypotension. During treatment with Cadramine-V (Diphenhydramine Hydrochloride) should avoid sun exposure. Should not be used during the drivers of vehicles and people, trade is connected with increased concentration. In the period of treatment should avoid drinking alcoholic beverages.
Cadramine-V (Diphenhydramine Hydrochloride) Xepa-Soul Pattinson drug interactions
When Cadramine-V (Diphenhydramine Hydrochloride) Xepa-Soul Pattinson applied simultaneously increases the effects of ethanol and drugs that depress the central nervous system.
With simultaneous use of Cadramine-V (Diphenhydramine Hydrochloride) Xepa-Soul Pattinson and MAO inhibitors increase the anticholinergic activity of Cadramine-V (Diphenhydramine Hydrochloride).
The antagonistic interaction observed with a joint appointment with psychostimulants.
Reduces the effectiveness of apomorphine as an emetic in the treatment of poisoning. Intensifies anticholinergic effects of drugs with anticholinergic activity.
Cadramine-V Xepa-Soul Pattinson in case of emergency / overdose
Symptoms: dry mouth, difficulty breathing, persistent mydriasis, flushing, depression or excitement (more common in children), CNS confusion; children - the development of convulsions and death.
Treatment: induction of vomiting, gastric lavage, the prescription of activated charcoal, symptomatic and supportive therapy on a background of careful monitoring of respiration and blood pressure levels.
Menthol:
Cadramine-V (Menthol) is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. It is a waxy, crystalline substance, clear or white in color, which is solid at room temperature and melts slightly above. The main form of Cadramine-V (Menthol) occurring in nature is (-)-menthol, which is assigned the (1R,2S,5R) configuration. Cadramine-V (Menthol) has local anesthetic and counterirritant qualities, and it is widely used to relieve minor throat irritation.
Indication: Used to treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.
Cadramine-V (Menthol) is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. Menthol's ability to chemically trigger cold-sensitive receptors in the skin is responsible for the well known cooling sensation that it provokes when inhalated, eaten, or applied to the skin. It should be noted that Cadramine-V (Menthol) does not cause an actual drop in temperature.
Zinc Oxide:
- Indications and usage
- Contraindications
- Warnings
- Precautions
- Adverse reactions
- Drug abuse and dependence
- Overdosage
- Dosage and administration
- How supplied
INDICATIONS AND USAGE
Cadramine-V (Zinc Oxide) 1 mg/mL (Zinc Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain Cadramine-V (Zinc Oxide) serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms.
CONTRAINDICATIONS
None known.
WARNINGS
Direct intramuscular or intravenous injection of Cadramine-V (Zinc Oxide) 1 mg/mL (Zinc Chloride Injection, USP) is contraindicated as the acidic pH of the solution (2) may cause considerable tissue irritation.
Severe kidney disease may make it necessary to reduce or omit chromium and Cadramine-V (Zinc Oxide) doses because these elements are primarily eliminated in the urine.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
PRECAUTIONS
General
Do not use unless the solution is clear and the seal is intact.
Zinc 1 mg/mL should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. Solution contains no preservatives; discard unused portion immediately after admixture procedure is completed.
Zinc should not be given undiluted by direct injection into a peripheral vein because of the likelihood of infusion phlebitis and the potential for increased excretory loss of Cadramine-V (Zinc Oxide) from a bolus injection. Administration of Cadramine-V (Zinc Oxide) in the absence of copper may cause a decrease in serum copper levels.
Laboratory Tests
Periodic determinations of serum copper as well as Cadramine-V (Zinc Oxide) are suggested as a guideline for subsequent Cadramine-V (Zinc Oxide) administration.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term animal studies to evaluate the carcinogenic potential of Cadramine-V 1 mg/mL (Zinc Chloride Injection, USP) have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cadramine-V (Zinc Oxide) 1 mg/mL (Zinc Chloride Injection, USP) is administered to a nursing woman.
Pediatric Use
Pregnancy Category C. Animal reproduction studies have not been conducted with Cadramine-V chloride. It is also not known whether Cadramine-V (Zinc Oxide) chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cadramine-V (Zinc Oxide) chloride should be given to a pregnant woman only if clearly needed.
Geriatric Use
An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
ADVERSE REACTIONS
None known.
DRUG ABUSE AND DEPENDENCE
None known.
OVERDOSAGE
Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult leukemic patients without toxic manifestations. However, acute toxicity was reported in an adult when 10 mg Cadramine-V (Zinc Oxide) was infused over a period of one hour on each of four consecutive days. Profuse sweating, decreased level of consciousness, blurred vision, tachycardia (140/min), and marked hypothermia (94.2° F) on the fourth day were accompanied by a serum Cadramine-V (Zinc Oxide) concentration of 207 mcg/dl. Symptoms abated within three hours.
Hyperamylasemia may be a sign of impending Cadramine-V (Zinc Oxide) overdosage; patients receiving an inadvertent overdose (25 mg zinc/liter of TPN solution, equivalent to 50 to 70 mg zinc/day) developed hyperamylasemia (557 to 1850 Klein units; normal: 130 to 310).
Death resulted from an overdosage in which 1683 mg Cadramine-V (Zinc Oxide) was delivered intravenously over the course of 60 hours to a 72 year old patient.
Symptoms of Cadramine-V (Zinc Oxide) toxicity included hypotension (80/40 mm Hg), pulmonary edema, diarrhea, vomiting, jaundice, and oliguria, with a serum Cadramine-V (Zinc Oxide) level of 4184 mcg/dl.
Calcium supplements may confer a protective effect against Cadramine-V (Zinc Oxide) toxicity.
DOSAGE AND ADMINISTRATION
Cadramine-V (Zinc Oxide) 1 mg/mL (Zinc Chloride Injection, USP) contains 1 mg zinc/mL and is administered intravenously only after dilution. The additive should be diluted prior to administration in a volume of fluid not less than 100 mL. For the metabolically stable adult receiving TPN, the suggested intravenous dosage is 2.5 to 4 mg zinc/day (2.5 to 4 mL/day). An additional 2 mg zinc/day (2 mL/day) is suggested for acute catabolic states. For the stable adult with fluid loss from the small bowel, an additional 12.2 mg zinc/liter of small bowel fluid lost (12.2 mL/liter of small bowel fluid lost), or an additional 17.1 mg zinc/kg of stool or ileostomy output (17.1 mL/kg of stool or ileostomy output) is recommended. Frequent monitoring of Cadramine-V (Zinc Oxide) blood levels is suggested for patients receiving more than the usual maintenance dosage level of Cadramine-V (Zinc Oxide).
For full term infants and children up to 5 years of age, 100 mcg zinc/kg/day (0.1 mL/kg/day) is recommended. For premature infants (birth weight less than 1500 g) up to 3 kg in body weight, 300 mcg zinc/kg/day (0.3 mL/kg/day) is suggested.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
HOW SUPPLIED
Cadramine-V (Zinc Oxide) 1 mg/mL (Zinc Chloride Injection, USP) is supplied in 10 mL Plastic Vials (List No. 4090).
Store at 20 to 25°C (68 to 77°F).
Revised: October, 2004
© Hospira 2004 EN-0488 Printed in USA
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
10 mL Vial
Cadramine-V (Zinc Oxide)
1 mg/mL
Cadramine-V (Zinc Oxide) Chloride Inj., USP
Rx only
FOR I.V. USE ONLY AFTER DILUTION.
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
Cadramine-V pharmaceutical active ingredients containing related brand and generic drugs:
Cadramine-V available forms, composition, doses:
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.